A citation-based method for searching scientific literature

David C Hornigold, Emma Roth, Victor Howard, Sarah Will, Stephanie Oldham, Matthew P Coghlan, Clemence Blouet, James L Trevaskis. Appetite 2018
Times Cited: 18







List of co-cited articles
406 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.
Jonathan W Day, Nickki Ottaway, James T Patterson, Vasily Gelfanov, David Smiley, Jas Gidda, Hannes Findeisen, Dennis Bruemmer, Daniel J Drucker, Nilika Chaudhary,[...]. Nat Chem Biol 2009
372
55


A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.
Brian Finan, Bin Yang, Nickki Ottaway, David L Smiley, Tao Ma, Christoffer Clemmensen, Joe Chabenne, Lianshan Zhang, Kirk M Habegger, Katrin Fischer,[...]. Nat Med 2015
331
50

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Philip Ambery, Victoria E Parker, Michael Stumvoll, Maximilian G Posch, Tim Heise, Leona Plum-Moerschel, Lan-Feng Tsai, Darren Robertson, Meena Jain, Marcella Petrone,[...]. Lancet 2018
132
50

Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
S J Henderson, A Konkar, D C Hornigold, J L Trevaskis, R Jackson, M Fritsch Fredin, R Jansson-Löfmark, J Naylor, A Rossi, M A Bednarek,[...]. Diabetes Obes Metab 2016
123
44

Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents.
J L Trevaskis, C Sun, J Athanacio, L D'Souza, M Samant, K Tatarkiewicz, P S Griffin, C Wittmer, Y Wang, C-H Teng,[...]. Diabetes Obes Metab 2015
40
44

A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials.
Joachim Tillner, Maximilian G Posch, Frank Wagner, Lenore Teichert, Youssef Hijazi, Christine Einig, Stefanie Keil, Torsten Haack, Michael Wagner, Martin Bossart,[...]. Diabetes Obes Metab 2019
78
44

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Juan Pablo Frias, Michael A Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E Gimeno, Zvonko Milicevic, Deborah Robins,[...]. Lancet 2018
293
44

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Tamer Coskun, Kyle W Sloop, Corina Loghin, Jorge Alsina-Fernandez, Shweta Urva, Krister B Bokvist, Xuewei Cui, Daniel A Briere, Over Cabrera, William C Roell,[...]. Mol Metab 2018
153
44

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Brian Finan, Tao Ma, Nickki Ottaway, Timo D Müller, Kirk M Habegger, Kristy M Heppner, Henriette Kirchner, Jenna Holland, Jazzminn Hembree, Christine Raver,[...]. Sci Transl Med 2013
307
38

Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
Alessandro Pocai, Paul E Carrington, Jennifer R Adams, Michael Wright, George Eiermann, Lan Zhu, Xiaobing Du, Aleksandr Petrov, Michael E Lassman, Guoqiang Jiang,[...]. Diabetes 2009
269
33

Gut hormone polyagonists for the treatment of type 2 diabetes.
Sara J Brandt, Anna Götz, Matthias H Tschöp, Timo D Müller. Peptides 2018
59
33

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.
Juan Pablo Frias, Edward J Bastyr, Louis Vignati, Matthias H Tschöp, Christophe Schmitt, Klara Owen, Rune Haubo Christensen, Richard D DiMarchi. Cell Metab 2017
148
33



Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Piotr A Mroz, Brian Finan, Vasily Gelfanov, Bin Yang, Matthias H Tschöp, Richard D DiMarchi, Diego Perez-Tilve. Mol Metab 2019
70
33

Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss.
Jens Juul Holst, Sten Madsbad, Kirstine N Bojsen-Møller, Maria Saur Svane, Nils Bruun Jørgensen, Carsten Dirksen, Christoffer Martinussen. Surg Obes Relat Dis 2018
73
33

The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers.
Tricia Tan, Preeshila Behary, George Tharakan, James Minnion, Werd Al-Najim, Nicolai J Wewer Albrechtsen, Jens J Holst, Stephen R Bloom. J Clin Endocrinol Metab 2017
50
33

A role for glucagon-like peptide-1 in the central regulation of feeding.
M D Turton, D O'Shea, I Gunn, S A Beak, C M Edwards, K Meeran, S J Choi, G M Taylor, M M Heath, P D Lambert,[...]. Nature 1996
27

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
27

Targeted estrogen delivery reverses the metabolic syndrome.
Brian Finan, Bin Yang, Nickki Ottaway, Kerstin Stemmer, Timo D Müller, Chun-Xia Yi, Kirk Habegger, Sonja C Schriever, Cristina García-Cáceres, Dhiraj G Kabra,[...]. Nat Med 2012
200
27

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
John B Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E Schmidt, Eduard Montanya, Jason H Brett, Marcin Zychma, Lawrence Blonde. Lancet 2009
27

Glucagon increases energy expenditure independently of brown adipose tissue activation in humans.
V Salem, C Izzi-Engbeaya, C Coello, D B Thomas, E S Chambers, A N Comninos, A Buckley, Z Win, A Al-Nahhas, E A Rabiner,[...]. Diabetes Obes Metab 2016
77
27

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Xavier Pi-Sunyer, Arne Astrup, Ken Fujioka, Frank Greenway, Alfredo Halpern, Michel Krempf, David C W Lau, Carel W le Roux, Rafael Violante Ortiz, Christine Bjørn Jensen,[...]. N Engl J Med 2015
786
27

The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans.
Akila De Silva, Victoria Salem, Christopher J Long, Aidan Makwana, Rexford D Newbould, Eugenii A Rabiner, Mohammad A Ghatei, Stephen R Bloom, Paul M Matthews, John D Beaver,[...]. Cell Metab 2011
201
27

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
Kathleen M Dungan, Santiago Tofé Povedano, Thomas Forst, José G González González, Charles Atisso, Whitney Sealls, Jessie L Fahrbach. Lancet 2014
293
27

Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids.
James L Trevaskis, Christine M Mack, Chengzao Sun, Christopher J Soares, Lawrence J D'Souza, Odile E Levy, Diane Y Lewis, Carolyn M Jodka, Krystyna Tatarkiewicz, Bronislava Gedulin,[...]. PLoS One 2013
26
27

Unimolecular Polypharmacy for Treatment of Diabetes and Obesity.
Matthias H Tschöp, Brian Finan, Christoffer Clemmensen, Vasily Gelfanov, Diego Perez-Tilve, Timo D Müller, Richard D DiMarchi. Cell Metab 2016
142
27

Gut hormone PYY(3-36) physiologically inhibits food intake.
Rachel L Batterham, Michael A Cowley, Caroline J Small, Herbert Herzog, Mark A Cohen, Catherine L Dakin, Alison M Wren, Audrey E Brynes, Malcolm J Low, Mohammad A Ghatei,[...]. Nature 2002
27

Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models.
Elizabeth A Killion, Jinghong Wang, Junming Yie, Stone D-H Shi, Darren Bates, Xiaoshan Min, Renee Komorowski, Todd Hager, Liying Deng, Larissa Atangan,[...]. Sci Transl Med 2018
77
27

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
Anna Secher, Jacob Jelsing, Arian F Baquero, Jacob Hecksher-Sørensen, Michael A Cowley, Louise S Dalbøge, Gitte Hansen, Kevin L Grove, Charles Pyke, Kirsten Raun,[...]. J Clin Invest 2014
408
27

Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study.
Natasha C Bergmann, Asger Lund, Lærke S Gasbjerg, Emma C E Meessen, Maria M Andersen, Sigrid Bergmann, Bolette Hartmann, Jens J Holst, Lene Jessen, Mikkel B Christensen,[...]. Diabetologia 2019
45
27

A Long-Acting PYY3-36 Analog Mediates Robust Anorectic Efficacy with Minimal Emesis in Nonhuman Primates.
Shamina M Rangwala, Katharine D'Aquino, Yue-Mei Zhang, Lindsay Bader, Wilson Edwards, Songmao Zheng, Annette Eckardt, Ann Lacombe, Rebecca Pick, Veronica Moreno,[...]. Cell Metab 2019
23
27

Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study.
Preeshila Behary, George Tharakan, Kleopatra Alexiadou, Nicholas Johnson, Nicolai J Wewer Albrechtsen, Julia Kenkre, Joyceline Cuenco, David Hope, Oluwaseun Anyiam, Sirazum Choudhury,[...]. Diabetes Care 2019
41
27

Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice.
Sigrid Jall, Stephan Sachs, Christoffer Clemmensen, Brian Finan, Frauke Neff, Richard D DiMarchi, Matthias H Tschöp, Timo D Müller, Susanna M Hofmann. Mol Metab 2017
62
22

Glucagon-like peptide-1 7-36: a physiological incretin in man.
B Kreymann, G Williams, M A Ghatei, S R Bloom. Lancet 1987
22

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.
Richard E Pratley, Michael A Nauck, Anthony H Barnett, Mark N Feinglos, Fernando Ovalle, Illana Harman-Boehm, June Ye, Rhona Scott, Susan Johnson, Murray Stewart,[...]. Lancet Diabetes Endocrinol 2014
220
22

Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively.
Nicola M Neary, Caroline J Small, Maralyn R Druce, Adrian J Park, Sandra M Ellis, Nina M Semjonous, Catherine L Dakin, Karin Filipsson, Fang Wang, Aysha S Kent,[...]. Endocrinology 2005
244
22

Molecular Integration of Incretin and Glucocorticoid Action Reverses Immunometabolic Dysfunction and Obesity.
Carmelo Quarta, Christoffer Clemmensen, Zhimeng Zhu, Bin Yang, Sini S Joseph, Dominik Lutter, Chun-Xia Yi, Elisabeth Graf, Cristina García-Cáceres, Beata Legutko,[...]. Cell Metab 2017
51
22

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.
Daniel J Drucker, John B Buse, Kristin Taylor, David M Kendall, Michael Trautmann, Dongliang Zhuang, Lisa Porter. Lancet 2008
734
22

Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice.
Tanvi Talsania, Younes Anini, Stephanie Siu, Daniel J Drucker, Patricia L Brubaker. Endocrinology 2005
234
22

Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21.
Timo D Müller, Lorraine M Sullivan, Kirk Habegger, Chun-Xia Yi, Dhiraj Kabra, Erin Grant, Nickki Ottaway, Radha Krishna, Jenna Holland, Jazzminn Hembree,[...]. J Pept Sci 2012
114
22

Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like Peptide 1 receptor deficiency.
Hilary E Wilson-Pérez, Adam P Chambers, Karen K Ryan, Bailing Li, Darleen A Sandoval, Doris Stoffers, Daniel J Drucker, Diego Pérez-Tilve, Randy J Seeley. Diabetes 2013
203
22

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Richard E Pratley, Vanita R Aroda, Ildiko Lingvay, Jörg Lüdemann, Camilla Andreassen, Andrea Navarria, Adie Viljoen. Lancet Diabetes Endocrinol 2018
248
22

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
Jesper Lau, Paw Bloch, Lauge Schäffer, Ingrid Pettersson, Jane Spetzler, Jacob Kofoed, Kjeld Madsen, Lotte Bjerre Knudsen, James McGuire, Dorte Bjerre Steensgaard,[...]. J Med Chem 2015
345
22

GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet.
Christoffer Clemmensen, Joseph Chabenne, Brian Finan, Lorraine Sullivan, Katrin Fischer, Daniela Küchler, Laura Sehrer, Teja Ograjsek, Susanna M Hofmann, Sonja C Schriever,[...]. Diabetes 2014
87
22


Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight.
C M Mack, C J Soares, J K Wilson, J R Athanacio, V F Turek, J L Trevaskis, J D Roth, P A Smith, B Gedulin, C M Jodka,[...]. Int J Obes (Lond) 2010
79
22


Inhibition of food intake in obese subjects by peptide YY3-36.
Rachel L Batterham, Mark A Cohen, Sandra M Ellis, Carel W Le Roux, Dominic J Withers, Gary S Frost, Mohammad A Ghatei, Stephen R Bloom. N Engl J Med 2003
22


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.